Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions

Journal of Applied Toxicology

Volumn 33, Issue 2, 2013, Pages 100-108

  Lee, Kye Sook ^a   Kim, Sang Kyum ^a  

^a Chungnam National University   (South Korea)

Author keywords

Cytochrome P450 inhibition; Drug metabolism; Drug drug interactions; Liquid chromatography tandem mass spectrometry; Metabolism dependent inhibition (MDI)

Indexed keywords

AMFEBUTAMONE; CARBAMAZEPINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DISULFIRAM; FLUOXETINE; FLUVOXAMINE; FURAFYLLINE; MEPHENYTOIN; METHOXSALEN; MIDAZOLAM; NICOTINAMIDE ADENINE DINUCLEOTIDE; PAROXETINE; PHENACETIN; TESTOSTERONE; TICLOPIDINE; TIENILIC ACID; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84871623034     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1720     Document Type: Article

References (30)

1. Allqvist A, Miura J, Bertilsson L, Mirghani RA. 2007. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinidine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol. 63: 173-179.
2. Ansede JH, Thakker DR. 2004. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J. Pharm. Sci. 93: 239-255.
3. Ayrton J, Plumb R, Leavens WJ, Mallett D, Dickins M, Dear GJ. 1998. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Commun. Mass Spectrom. 12: 217-224.
4. 50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab. Lett. 2: 51-59.
5. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. 1993. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 24: 1211-1214.
6. Bu HZ, Knuth K, Magis L, Teitelbaum P. 2000. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun. Mass Spectrom. 14: 1943-1948.
7. Chauret N, Gauthier A, Martin J, Nicole-Griffith DA. 1997. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse. Drug Metab. Dispos. 25: 1130-1136.
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108.
9. Christensen M, Tybring G, Mihara K, Yasui-Furukori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. 2002. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin. Pharmacol. Ther. 71: 141-152.
10. Crespi CL, Miller VP, Penman BW. 1997. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248: 188-190.
11. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. 2001. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos. 29: 23-29.
12. Dilmaghanian S, Gerber JG, Filler SG, Sanchez A, Gal J. 2004. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: testosterone and methadone as substrates. Chirality 16: 79-85.
13. Figgitt DP, McClellan KJ. 2000. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Drugs 60: 925-954.
14. Green MD, Jiang X, King CD. 2004. Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. Life Sci. 9: 947-953.
15. Grimm SC, Einolf HJ, Hall SD, He K, Lim HK, Ling K-HJ, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS. 2009. The conduct of in vitro studies to address time dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos. 37: 1355-1370.
16. Guengerich FP. 1997. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 43: 7-35.
17. Hemeryck A, Belpaire FM. 2002. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3: 13-37.
18. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. 2000. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28: 1176-1183.
19. Huang S, Stifano T. 2006. Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. US Department for Health and Human Services Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
20. Karjalainen MJ, Neuvonen PJ, Backman JT. 2008. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin. Pharmacol. Toxicol. 103: 157-165.
21. Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. 2005. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19: 2651-2658.
22. Kim SK, Novak RF. 2007. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol. Ther. 113: 88-120.
23. Miia T, Uusitalo J, Jalonen J, Pelkonen O. 2005. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur. J. Pharm. Sci. 24: 123-132.
24. Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 35: 246-255.
25. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. 1997. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem. Pharmacol. 53: 531-538.
26. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. 2008. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82: 667-715.
27. Spina E, Scordo MG. 2002. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19: 299-320.
28. VandenBrink BM, Isoherranen N. 2010. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr. Opin. Drug Discov. Devel. 13: 66-77.
29. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. 2003. Drug metabolism and drug interaction: Application and clinical value of in vitro models. Curr. Drug Metab. 4: 423-459.
30. Zhou S, Yung CS, Cher GB, Chan E, Duan W, Huang M, McLeod HL. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44: 279-304.